Core Viewpoint - Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of UnitedHealth Group Incorporated related to a Department of Justice investigation into the company's billing practices [1]. Group 1 - The investigation by the United States Department of Justice focuses on UnitedHealth's billing practices, which may indicate serious compliance issues [1]. - Investors currently holding shares of UnitedHealth are encouraged to seek more information and may contact Rosen Law Firm for assistance [2]. - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [3].

Core Insights - Humana Inc. (HUM) is well-positioned for growth due to improved premium revenues, an aging U.S. population, acquisitions, and strong cash generation abilities [1] - The company has a strong outlook for 2025, with anticipated revenue growth and earnings per share [3][4] Revenue Growth - Humana's premium revenues increased by 10.7% year over year in 2024, driven by a solid customer base in its Medicaid and Medicare operations [5] - The company expects revenues for 2025 to be between $126 billion and $128 billion, reflecting a 7.8% improvement from 2024 [3] Earnings Performance - Humana has consistently outperformed earnings estimates, with an average surprise of 15.35% over the last four quarters [2] Strategic Acquisitions - The company has pursued strategic acquisitions to enhance its capabilities and expand its footprint, including Family Physicians Group, Curo, Enclara, iCare, and Inclusa [7] - The acquisition of Enclara improved hospice pharmacy services, while the iCare deal expanded its Medicare presence in Wisconsin [7] Financial Position - As of December 31, 2024, Humana held cash and investment securities totaling $20.4 billion, significantly exceeding its long-term debt of $11.1 billion [8] - The company anticipates GAAP cash flow from operations to be between $2.4 billion and $2.9 billion for 2025, supporting its capital deployment strategy [8] Market Demand - The growing elderly population in the U.S. is expected to sustain demand for Humana's Medicare plans, supported by its CenterWell brand introduced in 2022 [6]

Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or ...

Market Overview - The American stock markets have experienced a downturn due to international tariff fears, impacting most sectors, while healthcare stocks have outperformed the general market in 2025 [1] Healthcare Sector Performance - Healthcare stocks are rising above competitors, with some appreciating by at least 30% this year, and smaller stocks seeing increases of 50% or more, indicating potential undervaluation [2] - Royalty Pharma has seen a 25% year-to-date price appreciation, with a current price of $31.37 and a 12-month price forecast of $41.60, suggesting a 32.61% upside [2][4] - CVS Health has experienced a 50% increase in share price since the beginning of the year, with a current price of $67.13 and a 12-month price forecast of $70.41, indicating a 4.89% upside [5][6] - Tempus AI has seen a 60% increase in share price year-to-date, with a current price of $47.83 and a 12-month price forecast of $61.18, suggesting a 27.92% upside [8][9] - Guardant Health's share prices have risen nearly 50% since the beginning of the year, with a current price of $43.14 and a 12-month price forecast of $48.95, indicating a 13.47% upside [11][12] Institutional Investments and Analyst Ratings - Royalty Pharma has seen significant institutional buying, with purchases rising to $748 million in Q4 2024 from $177 million in Q3 2024, and maintains a Buy rating from analysts [3] - CVS Health's short interest has fallen by over 12%, indicating increased investor confidence, and it has a Moderate Buy rating from analysts [7] - Tempus AI's quarterly revenue increased by 35.8% year-over-year to $200.7 million, with gross profit rising by 49.7% to $122.1 million, contributing to its positive analyst ratings [9][10] - Guardant Health has a consensus Buy rating from analysts, with actual revenue consistently beating estimates, although its path to profitability remains uncertain [13][14]

UNH CLIMBS HIGHER ON DOWN DAY FOR BROAD MARKETUnitedHealth Group, Inc. (UNH) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. Today, at 10:11 AM on March 20th, a significant trading signal occurred for UnitedHealth Group, Inc. (UNH) as it demonstrated a Power Inflow at a price of $505.54. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money ...

Core Viewpoint - The article discusses the reliability of Wall Street analysts' recommendations, particularly focusing on UnitedHealth Group (UNH), and emphasizes the importance of using these recommendations in conjunction with other research tools like the Zacks Rank [1][4]. Group 1: Brokerage Recommendations - UnitedHealth currently has an average brokerage recommendation (ABR) of 1.06, indicating a consensus between Strong Buy and Buy, with 23 out of 25 recommendations being Strong Buy [2]. - Strong Buy and Buy recommendations account for 92% and 8% of all recommendations, respectively [2]. Group 2: Limitations of Brokerage Recommendations - Studies indicate that brokerage recommendations have limited success in guiding investors towards stocks with the best price increase potential [4]. - Analysts often exhibit a strong positive bias due to the vested interests of brokerage firms, leading to a disproportionate number of Strong Buy recommendations compared to Strong Sell [5][9]. Group 3: Zacks Rank as an Alternative - The Zacks Rank, which classifies stocks from Strong Buy to Strong Sell based on earnings estimate revisions, is presented as a more reliable indicator of near-term price performance compared to ABR [7][10]. - The Zacks Rank is updated more frequently and reflects timely changes in earnings estimates, making it a better tool for predicting future stock prices [11]. Group 4: Current Status of UnitedHealth - The Zacks Consensus Estimate for UnitedHealth's earnings for the current year remains unchanged at $29.63, suggesting stable analyst views on the company's earnings prospects [12]. - Due to the unchanged consensus estimate and other factors, UnitedHealth holds a Zacks Rank of 3 (Hold), indicating a cautious approach despite the Buy-equivalent ABR [13].

While the current broad market sell-off dominates headlines, there's still value in looking at specific laggards from the major indexes. Among the blue-chip-laden Dow Jones Industrial Average (^DJI -1.30%), the two worst-performing stocks in the month of February were UnitedHealth Group (UNH 0.09%) and Salesforce (CRM -4.51%). They declined 12.5% and 12.8% last month, respectively, versus the Dow's much more modest dip of 1.6%. UnitedHealth's woes started early in February following hedge fund manager Bill ...

Core Insights - A significant majority of Americans (72%) rate the US healthcare system with a grade of C or lower, indicating widespread dissatisfaction with the current system [2] - Nearly half (46%) of respondents have faced the dilemma of choosing between paying medical bills and basic necessities over the past decade, highlighting financial strain related to healthcare [2] - A majority of Americans express willingness to reconsider key provisions of the Affordable Care Act (ACA) to make healthcare coverage more affordable [2] - There is strong support (66%) among Americans for banning direct advertisements from pharmaceutical companies, reflecting a consensus across political lines [2] - The survey indicates that 83% of respondents believe they should have the option to select health plans that exclude benefits they do not intend to use, if it results in cost savings [6] - Additionally, 56% of respondents feel that individuals with unhealthy lifestyles should incur higher health insurance costs [6] Research Methodology - The findings are based on a survey conducted in February 2025, involving over 1,000 respondents from the general US population [3]

Core Viewpoint - The article highlights two Dow Jones Industrial Average stocks, Johnson & Johnson and UnitedHealth Group, as strong investment opportunities, while Boeing is identified as a stock to avoid due to ongoing challenges and self-inflicted issues. Group 1: Johnson & Johnson - Johnson & Johnson is characterized as a low-volatility stock, with shares being less than half as volatile as the S&P 500 [3] - The company has a consistent demand for its healthcare products, leading to predictable cash flow, regardless of economic conditions [4] - A strategic shift towards brand-name drug development has resulted in innovative medicine accounting for nearly two-thirds of net sales [5] - Johnson & Johnson has achieved 35 consecutive years of adjusted operating earnings growth prior to the COVID-19 pandemic, showcasing its sustainable growth [6] - The company has had only 10 CEOs in its 139-year history, contributing to stability in leadership and growth initiatives [7] - Johnson & Johnson's forward price-to-earnings (P/E) ratio is below 15, and it has increased its quarterly dividend for 62 consecutive years, resulting in a 3% yield [8] Group 2: UnitedHealth Group - UnitedHealth Group is another healthcare stock recommended for purchase, despite a 24% decline from its all-time high [9] - The decline is attributed to a Department of Justice investigation, the death of a key executive, and a cybersecurity attack affecting millions [9] - The company has denied allegations regarding its Medicare Advantage insurance operations, indicating strong premium pricing power in the healthcare insurance sector [10] - UnitedHealth's Optum subsidiary is a significant growth driver, providing various healthcare services and growing sales faster than the traditional insurance segment [11] - The demand for healthcare services remains consistent, making UnitedHealth's business model resilient to economic fluctuations [12] - The company's shares are trading at a forward P/E multiple of 14, representing a 28% discount to its five-year average [13] Group 3: Boeing - Boeing is identified as a stock to avoid due to significant challenges, including a 60% decline from its all-time high and ongoing production issues [14][15] - The company has reported net losses totaling $35.7 billion over six consecutive years, primarily due to self-inflicted mechanical and delivery issues [16] - Boeing's balance sheet is concerning, having issued $18.2 billion in common stock to strengthen its financial position amid production challenges [17] - The Federal Reserve Bank of Atlanta's GDPNow forecast predicts a 2.8% contraction in U.S. GDP, historically correlating with poor performance for Boeing during recessions [18] - Investors are advised to adopt a wait-and-see approach regarding Boeing's recovery from its production issues and balance sheet concerns [19]

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...